PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports.

Several other research firms also recently commented on PDSB. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, PDS Biotechnology has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $0.22 on Wednesday. The company has a market capitalization of $12.40 million, a price-to-earnings ratio of -0.35 and a beta of 1.62. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a 12 month low of $0.20 and a 12 month high of $1.55. The stock’s 50 day moving average is $0.67 and its 200-day moving average is $0.82.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Equities research analysts expect that PDS Biotechnology will post -0.47 EPS for the current year.

Institutional Trading of PDS Biotechnology

Several large investors have recently modified their holdings of PDSB. Armistice Capital LLC bought a new stake in PDS Biotechnology during the fourth quarter worth about $2,182,000. BlackRock Inc. bought a new position in PDS Biotechnology in the 2nd quarter valued at about $535,000. Squarepoint Ops LLC raised its position in shares of PDS Biotechnology by 116.1% in the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after buying an additional 156,662 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of PDS Biotechnology by 117.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after acquiring an additional 106,300 shares during the period. Finally, Susquehanna International Group LLP lifted its holdings in shares of PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after acquiring an additional 80,937 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical?stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen?presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS?0101, is designed to treat HPV16?positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV?focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.